Wakamoto Pharmaceutical Co 4512.T · JPY

Its shares trade on Tokyo Stock Exchange under the ticker 4512.T. It has been listed since 16 May 1949. In the fiscal year to 31 March 2026, it reported revenue of ¥9.91bn and net income of ¥227.2m. At that date it held total assets of ¥16.50bn and shareholders' equity of ¥12.01bn.

Wakamoto Pharmaceutical Co., Ltd. engages in the manufacture and sale of ethical and non-prescription drugs. The company is headquartered in Chuo-Ku, Tokyo-To. The firm operates through four business segments. The Pharmaceuticals segment is involved in the manufacture and sale of innovator drugs, generic drugs and optiaid series supplements mainly in the ophthalmic field, as well as the commission of production and the sale of diagnostic drugs and raw materials in Japan. The Healthcare segment sales its core product Kawakami Wakamoto, the Avantbise series of medicated toothpastes that promote bad breath prevention based on evidence and Avantbise Oral Tablet mainly in the mail order business. The International segment is involved in the business related to the export of products and raw materials mainly in Asia and Europe, as well as the new license in and out business. The Real Estate Leasing segment is involved in the rental business of Coredo Muromachi.

Figures and description from our data supplier, not checked against the company's own report.

• Mr. Arata IgarashiPresident, Representative Director, since 2011
• Mr. Noboru YamazakiSenior Executive Officer, Manager of Business Planning
• Mr. Kimihiko SatoManaging Director, Chief Director of Healthcare Business, since 2014
• Mr. Sunao EharaExecutive Officer
• Mr. Mizuho KoikeExecutive Officer, Director of Accounting
• Mr. Hiroki SanadaExecutive Officer
• Mr. Makoto TaniguchiChief Director of Production, Sagami Oi Plant Manager, Director, since 2018
• Mr. Akimi YoshidaExecutive Officer
• Mr. Hiroyoshi KasaiChief Director of Pharmaceutical Development, Director of Pharmaceutical Development, Director of Product Strategy, Director, since 2017
• Mr. Akihiko TanigakiChief Director of Global Business, Director of Sales Planning, Director, since 2014
• Mr. Haruhisa HirataDirector
• Mr. Katsuyoshi EjimaIndependent Director

Overall

0

Environment

0

Social

0

Governance

0

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.